Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: A case report

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages

  Allen, Pamela B ^a   Koka, Rima ^a   Kleinberg, Michael E ^a   Baer, Maria R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CEFALEXIN; COTRIMOXAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; FUNGAL STRAIN; GENERAL PRACTITIONER; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; KARYOTYPING; LEG ULCER; LOADING DRUG DOSE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; RESPIRATORY FAILURE; SCEDOSPORIUM APIOSPERMUM; SKIN NECROSIS; SOFT TISSUE INFECTION; SUBCUTANEOUS TISSUE; TREATMENT DURATION;

AGED, 80 AND OVER; AMPUTATION; ANTIFUNGAL AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; LEG ULCER; LEUKEMIA, MYELOID, ACUTE; MYCOSES; PANCYTOPENIA; PYRIMIDINES; SCEDOSPORIUM; SOFT TISSUE INFECTIONS; TRIAZOLES;

EID: 84875749308     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.9489     Document Type: Article

References (21)

1. Blum W, Garzon R, Klisovic RB, et al: Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107:7473-7478, 2010.
2. Guarro J, Kantarcioglu AS, Horré R, et al: Scedosporium apiospermum: Changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 44:295-327, 2006. (Pubitemid 43922066)
3. Tadros TS, Workowski KA, Siegel MD, et al: Pathology and hyalohyphomycosis caused by Scedosproum apiospermum (Pseudallesheria boydii): An emerging mycosis. Hum Pathol 29:1266-1272, 1998. (Pubitemid 28525527)
4. Salkin IF, Mcginnis MR, Dyskstra MJ, et al: Scedosporium inflatum, an emerging pathogen. J Clin Microbiol 26:498-503, 1988. (Pubitemid 18062108)
5. Wood GM, McCormack JG, Muir DB, et al: Clinical features of human infections with Scedosporium inflatum. Clin Infect Dis 14:1027-1033, 1992.
6. Maslen M, Peel M: Human and animal isolates of Pseudallescheria boydii and Scedosporium species, from Melbourne, Australia, 1977-1995. Mycoses 54:442-449, 2011.
7. Warnock DW, Richardson MD: Fungal Infection in the Compromised Patient (ed 2). Chichester, United Kingdom, John Wiley & Sons, 1991, pp 311-353.
8. Takeuchi M, Yoshida C, Ota Y, et al: Deep skin infection of Scedosporium apiospermum in a patient with refractory idiopathic thrombocytopenic purpura. Intern Med 50:1339-1343, 2011.
9. Dworzack DL, Clark RB, Borkowski WJ, et al: Pseudallescheria boydii brain abscess: Association with near-drowning and efficacy of high-dose, prolonged miconazole therapy in patients with multiple abscesses. Medicine 68:218-224, 1989. (Pubitemid 19186159)
10. Steinbach WJ, Perfect JR: Scedosporium species infections and treatments. J Chemother 15:16-27, 2003. (Pubitemid 38021612)
11. Caira M, Girmenia C, Valentini CG, et al: Scedosporiosis in patients with acute leukemia: A retrospective multicenter report. Haematologica 93:104-110, 2008. (Pubitemid 351187612)
12. Gilgado F, Serena C, Cano J, et al: Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 50:4211- 4213, 2006. (Pubitemid 44865174)
13. Mellinghoff IK, Winston DJ, Mukwaya G, et al: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 34:1648-1650, 2002. (Pubitemid 34615452)
14. Ananda-Rajah MR, Grigg A, Slavin MA: Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia 166:83-86, 2008.
15. Girmenia C, Luzi G, Monaco M, et al. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report. J Clin Microbiol 36:1436-1438, 1998. (Pubitemid 28208045)
16. Walsh TJ, Lutsar I, Driscoll T, et al: Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21:240-248, 2002. (Pubitemid 34214142)
17. Walsh TJ, Peter J, McGough DA, et al: Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 39:1361-1364, 1995.
18. Cuenca-Estrella M, Ruiz-Diez B, Martínez-Suárez JV, et al: Comparative in-vitro activity of voriconazole (UK-109, 496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemotherapy 43:149-151, 1999. (Pubitemid 29045946)
19. Carrillo AJ, Guarro J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 45:2151-2153, 2001. (Pubitemid 32591717)
20. Przepiorka D, Buadi FK, McClune B: Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy 28:58-63, 2008.
21. Purkins L, Wood N, Greenhalgh K, et al: Voriconazole, a novel widespectrum triazole: Oral pharmacokinetics and safety. Br J Clin Pharmacol 56:10-16, 2003 (suppl 1). (Pubitemid 37491728)